/
PASG
$4.58-$0.01 (-0.33%)prev close
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$14.8M
3M shares
52-week range
$3.29 – $20.00
8% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Change$-212.23
Passage Bio, Inc. Common Stock
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.
www.passagebio.com- Employees
- 24
- IPO / List date
- Feb 28, 2020
- HQ
- PHILADELPHIA, PA
Held by traders on TradeandTell
No one on the platform currently holds PASG.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 133,612 | $1.0M |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2025-07-14 | 1-for-20reverse |
| 2004-06-01 | 20-for-1 |
Recent trades on TradeandTell
No one on the platform has traded PASG yet.
